特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

大手製薬会社の見通し

Big Pharma Outlook 2026

発行 Datamonitor Healthcare 商品コード 342057
出版日 ページ情報 英文 70 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=106.59円で換算しております。
大手製薬会社の見通し Big Pharma Outlook 2026
出版日: 2017年07月13日 ページ情報: 英文 70 Pages
概要

大手製薬会社は、強力な開発ポートフォリオ、高い潜在能力のあるパイプライン資産、先鋭的な高成長市場によって、成長が見込まれています。

当レポートでは、大手製薬会社の見通しについて調査分析し、戦略の促進要因、収益動向、治療分野など、体系的な情報を提供しています。

調査概要

アナリストの見通し

収益分析

  • 世界の収益概要
  • 企業の収益概要
  • 2024年の上位30製品
  • 大手製薬会社のパイプライン概要
  • 上位30パイプライン製品
  • 企業の開発ポートフォリオ
  • 5ヶ年の開発分析
  • 期限切れ収益の概要
  • 参考文献

治療分野分析

  • 世界の概要
  • 治療分野ランキング
  • オンコロジー
  • 内分泌疾患、代謝異常、遺伝性疾患
  • 中枢神経系
  • 参考文献

戦略分析

  • 大手製薬会社の戦略的適用
  • 対象となる取引
  • コスト削減プログラム
  • 大手製薬会社の市場プレゼンス
  • 参考文献

付録

図表

目次

Pharmavitae Analytics casts its eye out to 2026 with challenging trends in healthcare management set to crystallize, Big Pharma will add $29.5bn in revenues out to 2026, generating $351bn in prescription pharmaceuticals at a low single-digit compound annual growth rate (CAGR) of 0.9%. Using in-house sales forecasts, this analysis explores and visualizes market dynamics in the Big Pharma peer set out to 2026. A healthy launch portfolio will bolster growth as Big Pharma reaps the reward of breakthrough products as the result of recent industry innovation. By delving deeper into revenue trends, therapy area performance, and strategic drivers, this analysis is vital to understanding how Big Pharma will navigate headwinds in order to steer towards robust growth.

Key questions answered:

Revenue Analysis:

  • Which will be the best performing companies out to 2026?
  • Which companies will propel revenue growth over the forecast period?
  • How will Big Pharma perform across the US, 5EU, Japan and RoW regions?
  • Which companies will have leading market share gains and market share losses?
  • Explore the Pharmavitae Analytics Index and how the portfolio compares against specific criteria

Therapy area analysis:

  • What are the detailed competitive dynamics at play in the oncology, metabolic and, infectious diseases markets?
  • Which companies are building leadership in specific therapy area?
  • How are late-stage pipelines positioned and what are the most-coveted launch products?
  • How many new blockbuster positions will Big Pharma carve out to 2026?
  • Which therapy areas will experience the largest growth and decline?

Lifecycle analysis:

  • What are Big Pharma's relative growth rankings?
  • Which companies are reliant on pipeline launches to drive growth?
  • Which companies will be most affected by future biosimilar and generic erosion out to 2026?
  • How much is expected to be wiped off of Big Pharma's expiry portfolio?

Pipeline analysis:

  • What are the most coveted pipeline assets and which companies have the most valuable launch portfolios?
  • Which Big Pharma companies have the largest late-stage pipelines?
  • How does therapy area concentration for Big Pharma compare to the rest of the industry?
  • How is Big Pharma concentrated in regards to therapy area in late-stage assets?

Strategy analysis:

  • How is Big Pharma using licensing deals to propel growth and in what therapy areas are deals concentrated?
  • How is Big Pharma capitalizing on immuno-oncology using M&A and dealmaking?
  • Can data transform pharmaceutical R&D to maintain a supply of innovative treatments?
  • From R&D investment to externalization: where is Big Pharma maximizing value?

Highlights:

  • Big Pharma prescription drug sales are forecast to grow to $351bn by 2026 at a compound annual growth rate of 0.8%
  • Number one company in 2021: Pfizer sustains top ranking in prescription drug sales out to 2021
  • Number one company in 2026: Roche out-performs Pfizer out to 2026
  • Pharmavitae Index: Roche tops the index with a score calculated from 9 different metrics based on portfolios sales, pipelines, growth prospects and financials
  • Most valuable product: Keytruda will become the highest selling product with global sales forecast at $9bn
  • Most lucrative therapy area: Oncology will maintain the largest proportion of Big Pharma prescription sales out to 2026. Most valuable class: PD-1/PD-L1 inhibitors will continue to build momentum out to 2026
  • Pipeline launch analysis: Big Pharma's launch portfolio is set to add $58.3bn in revenues out to 2026

Table of Contents

  • Analyst Outlook
  • Revenue Analysis
  • Global prescription pharmaceutical revenue overview
  • Company performance ranking
  • Regional overview
  • Top class overview
  • Blockbuster tracker
  • Top 30 products in 2026
  • Bibliography
  • Pharmavitae Index
  • Therapy Area Analysis
  • Global overview
  • Therapy Area Focus: Oncology
  • Oncology: Analysis & Trends
  • Therapy Area Focus: Infectious Diseases
  • Infectious Diseases: Analysis & Trends
  • Therapy Area Focus: Central Nervous System
  • Central Nervous System: Analysis & Trends
  • Therapy Area Focus: CV & Metabolic
  • Metabolic: Analysis & Trends
  • Therapy Area Focus: Immunology & Inflammation
  • Bibliography
  • Lifecycle Analysis
  • Pipeline Analysis
  • Big Pharma pipeline overview
  • Top 20 pipeline products
  • Strategy Analysis
  • Big Pharma Licensing Trends 2012-16
  • Immuno-Oncology Deal Trends, 2012-16
  • Transforming Pharmaceutical R&D with Data
  • From R&D Investment to Externalization: Where is the Pharma Industry Maximizing Value?